pneumonia
remain
lead
caus
mortal
global
million
pneumonia
death
record
highest
incid
diseas
occur
young
children
estim
million
pneumonia
episod
occur
annual
children
less
five
year
old
occur
develop
world
incid
clinic
pneumonia
estim
episod
per
childyear
almost
threequart
childhood
pneumonia
death
occur
subsaharan
africa
southeast
asia
bacteri
pathogen
notabl
streptococcu
pneumonia
haemophilu
influenza
type
b
import
vaccineprevent
caus
pneumonia
virus
particular
influenza
respiratori
syncyti
viru
rsv
also
respons
larg
number
pneumonia
case
year
use
global
popul
data
children
age
five
year
estim
rsv
respons
million
episod
lower
respiratori
tract
infect
lrti
million
requir
hospit
admiss
death
similar
analys
data
influenza
virus
estim
caus
million
lrti
million
sever
lrti
death
children
age
less
five
year
review
death
either
lrti
occur
develop
world
virus
may
respons
lrti
rsv
influenza
children
age
five
year
viral
pathogen
associ
childhood
pneumonia
includ
adenovirus
human
metapneumoviru
hmpv
parainfluenza
virus
approxim
onethird
worldwid
refuge
popul
million
live
camp
camp
often
crowd
poor
sanit
provid
ideal
condit
transmiss
respiratori
pathogen
refuge
myanmar
burma
live
camp
thailand
sinc
lower
respiratori
tract
infect
estim
caus
death
respons
report
morbid
age
group
border
refuge
popul
overal
year
mortal
rate
per
give
estim
lrtispecif
mortal
rate
per
us
center
diseas
control
prevent
cdc
shoklo
malaria
research
unit
smru
establish
respiratori
viru
surveil
programm
burmes
refuge
popul
live
maela
camp
northwest
thailand
programm
includ
patient
admit
hospit
pneumonia
april
aim
inpati
surveil
determin
rel
burden
virusassoci
pneumonia
result
month
inpati
surveil
present
maela
camp
locat
rural
tak
provinc
approxim
km
bangkok
largest
nine
camp
thailandmyanmar
border
hous
approxim
peopl
area
continu
oper
sinc
karen
predomin
ethnic
camp
popul
gener
healthcar
provid
nongovernment
organis
international
puami
camp
resid
receiv
world
health
organis
expand
programm
immunis
epi
immunis
immunis
respiratori
pathogen
haemophilu
influenza
type
b
influenza
virus
streptococcu
pneumonia
avail
april
septemb
laboratoryenhanc
respiratori
surveil
undertaken
inpati
depart
ipd
maela
puami
hospit
throughout
period
train
local
health
worker
review
ipd
admiss
log
six
day
week
identifi
patient
admiss
diagnosi
pneumonia
includ
admit
seventh
day
health
worker
invit
pneumonia
patient
particip
enhanc
surveil
enrol
agre
enrol
patient
health
worker
complet
brief
symptom
questionnair
patient
interview
record
review
collect
nasopharyng
aspir
npa
previous
describ
patient
episod
subsequ
exclud
analys
fail
meet
surveil
case
definit
pneumonia
tabl
b
occur
within
day
previou
episod
patient
c
lack
adequ
laboratori
specimen
surveil
case
definit
base
devis
children
five
year
age
older
individu
satisfactori
clinic
case
definit
lack
surveil
case
definit
base
describ
british
thorac
societi
npa
specimen
ml
viral
transport
medium
vtm
prepar
inhous
transport
daili
smru
microbiolog
laboratori
locat
town
mae
sot
approxim
km
maela
specimen
place
insul
cool
box
immedi
collect
transport
back
mae
sot
laboratori
within
eight
hour
collect
store
analysi
viral
nucleic
acid
extract
thaw
npavtm
specimen
use
commerci
kit
follow
manufactur
instruct
qiaamp
viral
rna
minikit
qiagen
hilden
germani
april
septemb
viral
nucleic
acid
extract
protocol
magcor
autom
extractor
rbc
bioscienc
taiwan
octob
septemb
extract
analys
realtim
reversetranscript
pcr
rrtpcr
adenovirus
hmpv
influenza
virus
b
type
influenza
virus
detect
season
pandem
strain
rsv
describ
elsewher
intern
control
human
rnasep
pcr
includ
confirm
specimen
adequaci
identifi
pcr
inhibit
specimen
consid
posit
viru
pcr
ct
valu
appropri
run
control
result
ensur
reproduc
result
approach
assay
limit
detect
approxim
copi
per
reaction
target
smru
intern
qc
data
specimen
low
posit
pcr
result
ct
valu
repeat
ct
run
viru
pcr
consid
posit
clinic
laboratori
data
record
paperbas
case
record
form
subsequ
enter
access
databas
microsoft
redmond
wa
usa
systemat
check
error
comparison
origin
case
record
form
data
analys
stataic
version
statacorp
colleg
station
tx
usa
proport
analys
chisquar
fisher
exact
test
appropri
logist
regress
use
calcul
odd
ratio
confid
interv
ci
multivari
model
construct
determin
relationship
age
viral
detect
pneumonia
sever
year
old
antimicrobi
use
prior
admiss
twotail
pvalu
consid
signific
surveil
program
underw
ethic
regulatori
review
cdc
determin
meet
definit
research
local
ethic
review
maela
possibl
commenc
surveil
howev
surveil
activ
discuss
puami
staff
concern
address
prior
begin
project
verbal
consent
obtain
potenti
particip
parentleg
guardian
case
children
age
year
prior
enrol
surveil
programm
total
individu
sampl
patient
singl
episod
eight
patient
two
episod
one
three
episod
median
age
present
one
year
iqr
rang
six
hundr
forti
patient
age
year
tabl
significantli
male
year
age
group
compar
older
patient
vs
p
patient
present
median
day
symptom
onset
iqr
eighti
five
percent
pneumonia
episod
patient
age
year
classifi
sever
sever
vari
gender
durat
ill
prior
admiss
data
shown
children
age
year
less
like
sever
sever
pneumonia
compar
age
year
ci
p
treatment
document
episod
one
patient
receiv
antimicrobi
drug
commonli
amoxicillin
ampicillin
viral
nucleic
acid
detect
npa
specimen
rank
order
detect
rsv
npa
adenoviru
influenza
hmpv
influenza
b
detect
virus
vari
consider
age
tabl
patient
age
year
like
viral
nucleic
acid
detect
npa
compar
five
year
older
year
old
ci
p
year
old
ci
p
rsv
significantli
like
detect
patient
present
year
age
year
old
ci
p
year
old
ci
p
trend
seen
hmpv
although
statist
signific
result
small
number
infect
detect
older
children
adult
year
old
ci
p
year
old
ci
p
influenza
virus
commonli
detect
older
children
adult
compar
age
less
one
year
year
old
ci
p
year
old
ci
p
adenovirus
also
like
detect
age
one
year
year
old
ci
p
year
old
ci
p
figur
diagnosi
sever
sever
pneumonia
year
age
group
associ
detect
rsv
ci
p
trend
remain
although
associ
becam
statist
nonsignific
control
age
detect
virus
multivari
logist
regress
model
aor
ci
p
multivari
model
detect
adenoviru
aor
ci
p
influenza
viru
aor
ci
p
associ
lower
likelihood
sever
sever
pneumonia
diagnosi
multipl
virus
detect
specimen
two
virus
detect
specimen
adenoviru
rsv
influenza
rsv
adenoviru
plu
influenza
adenoviru
hmpv
three
virus
detect
two
specimen
adenoviru
influenza
hmpv
adenoviru
influenza
rsv
associ
multipl
viru
detect
age
sever
pneumonia
data
shown
viru
detect
vari
season
rsv
influenza
virus
hmpv
detect
wet
cool
season
wherea
adenoviru
detect
occur
year
round
peak
late
cold
hot
season
figur
interestingli
ageadjust
analysi
patient
receiv
antimicrobi
two
week
preced
admiss
like
rsv
pcr
posit
aor
ci
p
associ
seen
virus
season
influenza
account
influenza
viru
detect
identifi
subsequ
year
influenza
detect
increas
influenza
virus
pandem
influenza
detect
peak
influenza
viru
detect
influenza
b
found
subsequ
year
account
influenza
viru
detect
figur
twenti
five
patient
influenza
associ
pneumonia
admit
describ
detail
previou
manuscript
laboratoryenhanc
surveil
document
contribut
respiratori
virus
hospitalis
clinic
pneumonia
episod
occur
crowd
refuge
camp
thailandmyanmar
border
april
septemb
expect
vast
major
patient
age
less
five
year
virus
detect
nasopharynx
half
case
viru
detect
significantli
like
infant
compar
older
children
adult
although
number
adult
case
small
period
routin
hospit
surveil
detect
inpati
lrti
episod
includ
death
episod
children
five
year
therefor
ipd
pneumonia
episod
enhanc
surveil
report
account
ipd
lrti
episod
ipd
lrti
episod
children
age
less
five
year
episod
person
age
five
year
older
maela
data
add
scant
data
aetiolog
pneumonia
refuge
popul
result
broadli
consist
similar
surveil
programm
conduct
two
kenyan
refuge
camp
patient
sever
acut
respiratori
infect
sari
least
one
adenoviru
hmpv
influenza
ab
parainfluenza
viru
rsv
detect
kenya
surveil
adenoviru
commonest
viru
detect
specimen
follow
rsv
influenza
viru
detect
specimen
major
hospitalis
sari
case
children
less
five
year
age
result
pneumonia
aetiolog
studi
variou
locat
develop
world
confirm
high
preval
viru
detect
hospitalis
pneumonia
episod
young
children
rsv
frequent
identifi
commonest
viru
associ
sever
infect
signific
proport
rsv
infect
occur
first
year
life
although
primari
infect
reinfect
common
older
children
rsv
previous
document
signific
pathogen
maela
incid
rsvassoci
pneumonia
episod
per
childyear
risk
cohort
infant
follow
birth
two
year
age
result
confirm
rsv
lead
viru
associ
pneumonia
gener
maela
camp
popul
major
infect
young
children
two
rsv
infect
occur
patient
age
five
year
older
influenza
virus
detect
almost
patient
episod
pneumonia
figur
consist
previous
publish
data
influenza
hospitalis
simmerman
uyeki
determin
influenza
virus
detect
hospitalis
pneumonia
case
recent
review
east
southeast
asian
data
role
adenovirus
aetiolog
pneumonia
remain
unclear
frequent
reinfect
persist
young
children
make
detect
npa
specimen
time
pneumonia
diagnosi
difficult
interpret
recent
studi
kenya
undertaken
part
multicentr
paediatr
pneumonia
aetiolog
studi
perch
find
higher
odd
adenoviru
detect
pneumonia
case
compar
control
studi
detect
rsv
upper
respiratori
tract
signific
associ
hospitalis
pneumonia
definit
clinic
pneumonia
childhood
use
enhanc
surveil
maela
definit
design
optim
sensit
diagnosi
potenti
lifethreaten
bacteri
infect
resourcepoor
set
accept
overdiagnosi
unnecessari
treatment
would
occur
demonstr
south
african
studi
virusassoci
pneumonia
reduc
third
children
given
nineval
pneumococc
conjug
vaccin
proport
virusposit
individu
would
secondari
bacteri
infect
mani
receiv
unnecessari
cours
antibiot
recent
work
pakistan
confirm
placebo
amoxicillin
equival
efficaci
nonsever
pneumonia
oral
amoxicillin
home
accept
altern
hospit
admiss
parenter
antibiot
sever
pneumonia
maela
almost
patient
treat
least
one
antimicrobi
drug
yet
third
exclud
adenoviru
proven
viral
infect
collect
find
point
like
treatment
viral
infect
children
defin
pneumonia
may
contribut
rise
preval
antimicrobi
resist
develop
world
enhanc
surveil
system
sever
limit
hospitalis
pneumonia
episod
captur
therefor
possibl
calcul
virusspecif
incid
rate
estim
repres
patient
enrol
comparison
enhanc
surveil
result
routin
surveil
figur
problemat
howev
note
direct
comparison
made
enhanc
surveil
includ
lrti
episod
identifi
routin
surveil
children
five
year
age
episod
patient
age
five
year
older
differ
case
definit
use
routin
surveil
compar
enhanc
surveil
like
explan
discrep
age
group
definit
almost
ident
ie
whobas
older
age
group
lrti
defin
routin
surveil
presenc
fever
plu
cough
sore
throat
short
breathdifficulti
breath
absenc
requir
abnorm
chest
sign
like
result
inclus
mani
nonpneumonia
case
within
lrti
categori
low
number
death
record
system
suggest
sever
signific
reason
noninclus
also
sinc
puami
hospit
gener
medic
admiss
unit
within
camp
signific
number
patient
miss
result
admiss
hospit
howev
remain
possibl
older
particip
repres
entir
hospitalis
pneumonia
patient
group
addit
sever
data
eg
need
supplement
oxygen
length
stay
outcom
data
collect
limit
conclus
drawn
surveil
comparison
made
studi
panel
virus
test
includ
key
pathogen
evid
associ
pneumonia
proven
inclus
pcr
assay
detect
addit
respiratori
virus
would
ad
valu
may
identifi
higher
preval
multipl
infect
studi
use
multiplex
viru
pcr
assay
detect
increas
proport
children
singl
multipl
viral
lower
respiratori
infect
human
bocaviru
rhinovirus
may
detect
larg
proport
pneumonia
case
although
data
regard
causal
studi
still
limit
despit
demonstr
influenza
viru
andor
rsv
associ
third
hospitalis
pneumonia
episod
maela
cost
inpati
pneumonia
treatment
high
two
recent
studi
estim
averag
cost
per
district
hospit
pneumonia
admiss
us
kenya
us
thailand
influenza
infect
vaccin
prevent
vaccin
prevent
rsv
infect
remain
elus
although
progress
continu
made
inclus
influenza
immunis
rsv
immunis
becom
avail
immunis
programm
refuge
thailandmyanmar
border
would
like
significantli
reduc
burden
pneumonia
requir
hospitalis
virus
commonli
identifi
burmes
refuge
admit
hospit
clinicallydiagnos
pneumonia
use
influenza
immunis
develop
vaccin
target
common
respiratori
virus
would
like
reduc
incid
pneumonia
children
live
refuge
camp
similar
set
author
declar
compet
interest
pt
vc
ct
cd
cp
lo
fn
conceiv
surveil
project
nc
ct
respons
specimen
data
collect
ww
perform
laboratori
work
pt
vc
data
analysi
pt
prepar
first
draft
manuscript
author
review
contribut
revis
manuscript
author
read
approv
final
manuscript
prepubl
histori
paper
access
http
